P2RY14 Antibody

What is P2RY14 and why is it important in research?

P2RY14 is a UDP-glucose-specific G protein-coupled receptor that plays critical roles in signaling by G-protein-coupled receptors (GPCR) and peptide ligand-binding receptors. It functions through Gi protein to inhibit adenylate cyclase, thereby decreasing cAMP levels in cells . The importance of P2RY14 in research stems from its involvement in multiple biological processes:

• In stem/progenitor cells, P2RY14 inhibits cell senescence by monitoring and responding to extracellular manifestations of tissue stress

• It has emerged as a potential biomarker for tumor microenvironment immunomodulation in head and neck squamous cell carcinoma (HNSC)

• P2RY14 plays a role in the homeostasis of hematopoietic stem/progenitor cells

• It regulates Schwann cell precursor self-renewal and has implications in neurofibroma development

Understanding these diverse functions makes P2RY14 antibodies valuable tools for investigating cellular signaling, immune modulation, and pathological conditions.

What are the validated applications for P2RY14 antibodies?

P2RY14 antibodies have been validated for multiple research applications, each requiring specific protocols and optimization:

• Western Blotting (WB): Typically used at dilutions of 1:100-400 to detect P2RY14 protein expression levels

• Immunocytochemistry (ICC): Effective at dilutions of 1:100-500 in formalin-fixed cells

• Immunohistochemistry in paraffin sections (IHC-P): Used at dilutions of 1:50-200

• Immunohistochemistry in frozen sections (IHC-F): Applied at dilutions of 1:100-500

• Enzyme-Linked Immunosorbent Assay (ELISA): Functional at dilutions of 1:100-200

• Flow cytometry (FACS): Used for detecting P2RY14 in cellular populations

Researchers should note that optimal working dilutions may vary depending on the specific experimental conditions and must be determined by the end user.

How should P2RY14 antibodies be validated before experimental use?

Proper validation of P2RY14 antibodies is essential to ensure experimental reproducibility and reliability. A comprehensive validation approach should include:

• Specificity testing: Verify that the antibody recognizes the intended target (P2RY14) and not other proteins by:

  • Using positive controls (cells/tissues known to express P2RY14)

  • Including negative controls (cells/tissues with low or no P2RY14 expression)

  • Employing knockout or knockdown models where available

• Application-specific validation:

  • For Western blotting: Confirm the antibody detects a band of the expected molecular weight

  • For IHC/ICC: Verify subcellular localization matches known distribution patterns

  • For ELISA: Establish standard curves using recombinant P2RY14 proteins

• Cross-reactivity assessment: Test the antibody against similar proteins (other P2Y family members) to ensure specificity

The antibody's ability to recognize human P2RY14 should be carefully assessed, particularly when recombinant P2RY14 (Pro51~Arg303) is used as the immunogen .

How can P2RY14 antibodies be used to investigate tumor microenvironment immunomodulation?

P2RY14 has emerged as a potential biomarker of tumor microenvironment (TME) immunomodulation, particularly in head and neck squamous cell carcinoma (HNSC). Researchers can employ P2RY14 antibodies to investigate this role through multiple approaches:

• Tumor infiltrating immune cell analysis:

  • Use multicolor immunofluorescence with P2RY14 antibodies alongside immune cell markers to characterize correlations between P2RY14 expression and specific immune cell populations

  • Research has identified correlations between P2RY14 expression and 15 tumor-infiltrating immune cells (TICs), including positive correlations with naïve B cells, CD8+ T cells, activated memory CD4+ T cells, Tregs, and resting mast cells

• Prognostic significance assessment:

  • Apply P2RY14 antibodies in tissue microarrays of patient samples to correlate expression levels with clinical outcomes

  • Studies have shown that HNSC patients with high P2RY14 expression had longer survival than those with low expression

• TME status characterization:

  • Combine P2RY14 immunostaining with metabolic markers to evaluate the transition between immune-dominant and metabolic-dominant TME states

  • Downregulation of P2RY14 has been identified as an indicator for conversion of TME status from immune-dominant to metabolic-dominant status

• Pathway analysis:

  • Use P2RY14 antibodies alongside other molecular markers to investigate immune-associated signaling pathways, particularly T-cell receptor signaling and PD-L1/PD-1 checkpoint pathways

What methodologies can be employed to study P2RY14's role in Schwann cell biology?

P2RY14 plays a significant role in Schwann cell precursor (SCP) self-renewal and neurofibroma development. Researchers can investigate this role using the following methodological approaches:

• In vitro SCP sphere formation assays:

  • Use P2RY14 antibodies to track receptor expression during sphere formation

  • Compare wild-type and Nf1-/- SCPs to assess differences in P2RY14 expression and localization

  • Correlate P2RY14 expression with self-renewal capacity as measured by sphere formation efficiency

• Pharmacological inhibition studies:

  • Combine P2RY14 antibody staining with treatment using selective P2RY14 inhibitors like PPTN (4-[4-(4-piperidinyl)phenyl]-7-[4-(trifluoromethyl)phenyl]-2-naphthalenecarboxylic acid)

  • Monitor changes in receptor expression, localization, and downstream signaling after inhibitor treatment

• cAMP signaling analysis:

  • Use P2RY14 antibodies alongside cAMP measurement techniques to correlate receptor expression with cAMP levels

  • Investigate how P2RY14 inhibition affects cAMP levels and subsequent cellular responses

• In vivo knockout studies:

  • Use P2RY14 antibodies to confirm knockout efficiency in transgenic models

  • Analyze changes in SC proliferation, nerve morphology, and tumor initiation in P2RY14 knockout mice

How can researchers optimize immunohistochemistry protocols for P2RY14 detection in different tissue types?

Optimizing immunohistochemistry (IHC) protocols for P2RY14 detection requires careful consideration of tissue-specific factors:

• Tissue fixation and antigen retrieval:

  • For formalin-fixed paraffin-embedded (FFPE) sections, use dilutions of 1:50-200

  • For frozen sections, use dilutions of 1:100-500

  • Test multiple antigen retrieval methods (heat-induced vs. enzymatic) to determine which best exposes P2RY14 epitopes in your specific tissue

• Background reduction strategies:

  • Block endogenous peroxidase activity with hydrogen peroxide

  • Use species-matched normal serum to block non-specific binding

  • Include washing steps with detergent to reduce background staining

• Signal amplification techniques:

  • For tissues with low P2RY14 expression, consider tyramide signal amplification

  • Evaluate biotin-free detection systems to avoid endogenous biotin interference in certain tissues

• Validation across tissue types:

  • Compare staining patterns in epithelial, nervous system, and immune tissues to account for tissue-specific expression patterns

  • Include positive control tissues with known P2RY14 expression (e.g., head and neck cancer samples)

What are common technical challenges when using P2RY14 antibodies in Western blotting?

Researchers frequently encounter challenges when using P2RY14 antibodies for Western blotting. The following methodological approaches can address these issues:

• Protein extraction optimization:

  • Use specialized extraction buffers containing appropriate detergents for membrane proteins like P2RY14

  • Consider non-denaturing conditions if antibody recognition depends on tertiary structure

  • Avoid excessive heat during sample preparation which may cause aggregation of membrane proteins

• Blocking and antibody concentration:

  • Test different blocking agents (milk vs. BSA) as P2RY14 detection may be sensitive to specific blockers

  • Optimize primary antibody concentration (recommended range: 1:100-400)

  • Extend incubation times at lower temperatures (4°C overnight) for improved specificity

• Band identification issues:

  • Verify band specificity using positive controls with recombinant P2RY14 (Pro51~Arg303)

  • Be aware that post-translational modifications may affect apparent molecular weight

  • Use loading controls appropriate for membrane proteins rather than conventional cytosolic markers

• Signal enhancement strategies:

  • For weak signals, consider using enhanced chemiluminescent (ECL) detection with 5μL of quality control per well

  • Optimize secondary antibody concentration and incubation conditions

How can researchers correlate P2RY14 expression with immune cell infiltration in tumors?

Investigating correlations between P2RY14 expression and immune cell infiltration requires sophisticated methodological approaches:

• Multiplex immunofluorescence analysis:

  • Design panels that include P2RY14 antibodies alongside markers for key immune cell populations (CD8+ T cells, naïve B cells, macrophages, etc.)

  • Use spectral unmixing to resolve overlapping fluorescent signals

  • Perform spatial analysis to assess co-localization or proximity patterns

• Computational analysis approaches:

  • Apply algorithms like CIBERSORT to deconvolute immune cell populations in relation to P2RY14 expression

  • Utilize the ESTIMATE algorithm to derive immune/stromal/estimate scores

  • Perform correlation analyses between P2RY14 expression levels and specific TIC populations

• Single-cell analysis integration:

  • Combine P2RY14 immunostaining with single-cell RNA sequencing data to correlate protein expression with transcriptomic profiles of immune cells

  • Validate findings using flow cytometry with P2RY14 antibodies to detect expression in specific immune cell subsets

• Functional validation:

  • Following observation of correlations (such as the positive correlation with naïve B cells, CD8+ T cells, and activated memory CD4+ T cells ), design functional assays to test mechanistic relationships

What considerations are important when designing co-immunoprecipitation experiments with P2RY14 antibodies?

Co-immunoprecipitation (Co-IP) is valuable for investigating P2RY14 protein interactions, but requires careful methodological planning:

• Antibody selection and validation:

  • Verify that the P2RY14 antibody can recognize the native (non-denatured) form of the protein

  • Test antibody efficiency in immunoprecipitating P2RY14 before proceeding to interaction studies

  • Consider epitope location—antibodies targeting extracellular domains may be more effective for membrane proteins like P2RY14

• Lysis conditions optimization:

  • Use mild, non-denaturing detergents (e.g., Digitonin, CHAPS, or NP-40) to preserve protein-protein interactions

  • Include appropriate protease and phosphatase inhibitors

  • Adjust salt concentration to maintain specific interactions while reducing background

• Control implementation:

  • Include isotype-matched control antibodies to identify non-specific binding

  • Use cells with knocked-down or knocked-out P2RY14 as negative controls

  • Consider reciprocal Co-IPs to confirm interactions (pull down with suspected interacting protein and blot for P2RY14)

• Interaction verification:

  • Follow Co-IP with Western blotting using P2RY14 antibodies at recommended dilutions (1:100-400)

  • Validate interactions through complementary methods (proximity ligation assay, FRET, etc.)

  • Focus on potential interactions with proteins identified in P2RY14-associated pathways such as T-cell receptor signaling pathway components or PD-1/PD-L1 checkpoint molecules

How can P2RY14 antibodies be used to investigate its role as a prognostic biomarker in cancer?

P2RY14 has shown potential as a prognostic biomarker, particularly in head and neck cancer. Researchers can explore this role using the following methodological approaches:

• Tissue microarray analysis:

  • Apply P2RY14 antibodies to tissue microarrays containing samples from patients with known clinical outcomes

  • Standardize staining protocols and scoring systems to ensure reproducibility

  • Stratify patients by P2RY14 expression levels and correlate with survival data

• Combined biomarker panels:

  • Integrate P2RY14 staining with other potential biomarkers identified through gene co-expression analysis

  • Focus on genes enriched in the T cell receptor signaling pathway and PD-1 checkpoint pathway that showed co-expression with P2RY14, such as Zap70, PIK3R1, CD4, CD28, CD3D/E/G, CD247, NFATC2, LCK, and PDCD1

  • Develop multivariate models to assess the combinatorial prognostic value

• Correlation with TNM staging:

  • Use P2RY14 antibodies on samples from different TNM stages to validate the negative correlation observed between P2RY14 expression and TNM stages in HNSC patients

  • Assess whether P2RY14 staining provides additional prognostic value beyond conventional staging

• Therapy response prediction:

  • Analyze P2RY14 expression in pre-treatment biopsies and correlate with response to specific therapies, particularly immunotherapies

  • Investigate whether P2RY14 expression changes correlate with development of therapy resistance

What methodological approaches are needed to investigate P2RY14's impact on cAMP signaling pathways?

Investigating P2RY14's role in cAMP signaling requires sophisticated methodological approaches:

• Real-time cAMP monitoring:

  • Use FRET-based cAMP sensors in conjunction with P2RY14 antibody staining to correlate receptor expression with cAMP dynamics

  • Apply P2RY14 agonists (UDP-glucose) or antagonists (PPTN) and monitor immediate changes in cAMP levels

  • Compare responses in wild-type cells versus cells with altered P2RY14 expression

• Downstream signaling analysis:

  • Use phospho-specific antibodies to monitor phosphorylation states of cAMP-dependent protein kinase (PKA) substrates following P2RY14 modulation

  • Correlate these changes with P2RY14 expression levels as detected by antibody staining

  • Implement pharmacological interventions targeting different components of the cAMP pathway

• Cell-type specific investigations:

  • Apply P2RY14 antibodies to identify receptor expression in specific cell populations (Schwann cells, hematopoietic stem/progenitor cells)

  • Use cell sorting based on P2RY14 expression to isolate populations for detailed cAMP signaling analysis

  • Compare cAMP responses between P2RY14-high and P2RY14-low populations

• In vivo signaling models:

  • Develop transgenic models with cAMP reporters and use P2RY14 antibodies to correlate receptor expression with in vivo cAMP dynamics

  • Evaluate how P2RY14 knockout affects baseline and stimulated cAMP levels in relevant tissues

How should researchers interpret discrepancies in P2RY14 antibody staining patterns between different tissues?

When researchers encounter variable P2RY14 antibody staining patterns across tissues, methodical analysis is required:

• Tissue-specific expression level analysis:

  • Compare staining intensity and patterns with published transcriptomic and proteomic data

  • Consider natural variation in P2RY14 expression across tissues (e.g., higher expression may be expected in certain immune cells versus epithelial tissues)

  • Validate findings with multiple antibodies targeting different epitopes of P2RY14

• Post-translational modification considerations:

  • Investigate whether tissue-specific post-translational modifications affect epitope accessibility

  • Test whether different fixation or antigen retrieval methods reveal consistent patterns

  • Consider using antibodies that recognize different regions of P2RY14 (e.g., extracellular versus intracellular domains)

• Receptor internalization and trafficking:

  • Assess whether differences reflect varying subcellular localization rather than expression levels

  • Compare membrane versus cytoplasmic staining patterns across tissues

  • Correlate with functional states (e.g., activated versus resting cells)

• Technical validation:

  • Implement rigorous controls for each tissue type, including positive controls (recombinant P2RY14 Pro51~Arg303)

  • Standardize quantification methods across tissues

  • Consider orthogonal validation methods (RNA-scope, Western blotting, flow cytometry)

What quantitative approaches are recommended for analyzing P2RY14 expression in immunohistochemistry studies?

Quantitative analysis of P2RY14 immunohistochemistry requires systematic methodological approaches:

• Digital image analysis optimization:

  • Develop tissue-specific algorithms for automated detection of P2RY14 positive cells

  • Implement machine learning approaches to distinguish specific staining from background

  • Standardize image acquisition parameters (exposure, white balance, resolution)

• Scoring system development:

  • Create multi-parameter scoring systems that account for:

    • Staining intensity (negative, weak, moderate, strong)

    • Percentage of positive cells

    • Subcellular localization patterns

  • Validate scoring systems through inter-observer concordance testing

• Spatial analysis considerations:

  • Analyze P2RY14 expression in relation to tissue architecture (e.g., tumor center versus invasive margin)

  • Implement nearest neighbor analysis to evaluate spatial relationships between P2RY14-positive cells and other cell types

  • Consider gradient analysis to detect patterns of expression change within tissues

• Statistical analysis selection:

  • Use appropriate statistical methods for comparing P2RY14 expression across different conditions

  • Implement survival analysis methods (Kaplan-Meier, Cox regression) when correlating expression with clinical outcomes

  • Consider multivariate models that account for confounding factors